X4 Pharmaceuticals, Inc (XFOR) stock
Close on Nov 12, 2026Market cap $314.30MP/E –Yield –
X4 Pharmaceuticals, Inc grew revenue 73.7% to $9.90M over the twelve months to Sep 30, 2026. Free cash flow was -$85.62M. At the latest close the market valued the company at $314.30M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $314.30M
- P/E ratio
- –
- Price to sales
- 31.75
- Price to book
- 2.26
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $9.90M
- Net income
- -$80.52M
- EPS, diluted
- -$1.87
- Free cash flow
- -$85.62M
- Book value per share
- $1.10
- Diluted shares
- 127M
Trading
- Previous close
- $3.23
- Open
- $3.16
- Day's range
- $2.95 – $3.20
- Volume
- 2,164,084
- Average volume (20 days)
- 764,363
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.42
- 52-week range
- $2.43 – $4.83
- RSI (14 days)
- 52.5
- Volatility (1 year)
- 72.1%
- Relative volume
- 0.99×
- WACC
- 12.0%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | XFOR | S&P 500 | Difference | XFOR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.4% | -2.7% | +15.1 pts | ||
| 3 months | -26.1% | -1.7% | −24.4 pts | ||
| Year to date | -20.8% | +11.9% | −32.6 pts | ||
| 1 year | -18.1% | +12.0% | −30.1 pts | ||
| 3 years | -85.9% | +78.2% | −164.1 pts | -48.0% | +21.2% |
| 5 years | -97.8% | +73.2% | −171.1 pts | -53.6% | +11.6% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases X4 Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- News
- News
- Update
- Results
About X4 Pharmaceuticals
Biological Products, (No Diagnostic Substances)
The company is a biopharmaceutical business dedicated to creating and commercializing targeted therapies for rare hematological disorders. Its core asset is mavorixafor, an orally administered CXCR4 chemokine receptor antagonist formulated as a capsule. The company markets XOLREMDI (mavorixafor), an FDA-approved prescription medicine for patients aged twelve and older with WHIM syndrome, an ultra-rare primary immunodeficiency and neutropenic condition. In addition to commercializing this therapy, the enterprise is conducting a global Phase 3 clinical trial evaluating mavorixafor for individuals suffering from chronic neutropenia.
Company profile, executives and historyX4 Pharmaceuticals stock: common questions
What is X4 Pharmaceuticals's stock price?
XFOR closed at $3.17 on Nov 12, 2026, down 1.86% on the day. Over the past 52 weeks it traded between $2.43 and $4.83.
What is X4 Pharmaceuticals's market cap?
X4 Pharmaceuticals was worth $314.30M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is XFOR's P/E ratio?
X4 Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$1.87), so it has no meaningful P/E ratio.
How much revenue does X4 Pharmaceuticals make?
X4 Pharmaceuticals reported revenue of $9.90M for the twelve months to Sep 30, 2026, up 73.7% from a year earlier.
Does X4 Pharmaceuticals pay a dividend?
No. X4 Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has XFOR stock performed over the past year?
Including dividends, XFOR returned -18.1% over the past year, against +12.0% for the S&P 500.
How many XFOR shares are sold short?
8M shares were sold short at the latest FINRA report, 9.16% of the float, or 10.9 days of average trading volume.
Who are X4 Pharmaceuticals's competitors?
Companies most similar to X4 Pharmaceuticals by business, industry and size include CRBU, RLAY, ELOX, CRSP, IPHA.
See a number that looks wrong?